BioVie Inc. (BIVIW)Carson City, United States | NasdaqCM
0.50 USD
|
Hot Take ↕ | July 11, 2026, 5:32 a.m. EDT
The immediate outlook is severely bearish as the stock trades at its 52-week low, indicating a complete lack of near-term momentum or technical support. Fundamentally, the company is in distress with massive cash burn, negative free cash flow, and significant losses on both assets and equity, suggesting a deteriorating business model rather than a temporary setback. There is no dividend income to offset these risks, and the absence of a price history makes any long-term assessment impossible, leaving investors with a high-risk speculative position devoid of safety margins. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 1.895 |
| Beta | 0.58 |
| Website | https://bioviepharma.com |
| Attribute | Value |
|---|---|
| Address1 | 680 W. Nye Lane |
| Address2 | Suite 204 |
| Ask | 0.2 |
| Ask Size | 1 |
| Beta | 0.575 |
| Bid | 0.4325 |
| Bid Size | 1 |
| Book Value | 2.069 |
| City | Carson City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.5025 |
| Current Ratio | 9.966 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.5025 |
| Day Low | 0.5025 |
| Debt To Equity | 1.895 |
| Display Name | BioVie |
| Ebitda | -20,365,984 |
| Ebitda Margins | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.5025 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.5025 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.5025 - 0.5025 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,783,690,200,000 |
| Float Shares | 7,501,943 |
| Free Cashflow | -13,481,777 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,025-08-08 |
| Language | en-US |
| Long Business Summary | BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada. |
| Long Name | BioVie Inc. |
| Market | us_market |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_242387715 |
| Net Income To Common | -19,960,016 |
| Open | 0.525 |
| Operating Cashflow | -20,510,668 |
| Operating Margins | 0.0 |
| Phone | 775 888 3162 |
| Previous Close | 0.5025 |
| Price Hint | 4 |
| Price To Book | 0.24287096 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.017 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.5025 |
| Regular Market Day Low | 0.5025 |
| Regular Market Day Range | 0.5025 - 0.5025 |
| Regular Market Open | 0.525 |
| Regular Market Previous Close | 0.5025 |
| Regular Market Price | 0.5025 |
| Regular Market Time | 1,783,713,600 |
| Regular Market Volume | 34 |
| Return On Assets | -0.61042 |
| Return On Equity | -1.06433 |
| Sand P52 Week Change | 0.20847368 |
| Sector | |
| Sector Key | |
| Short Name | BioVie Inc. Warrant |
| Source Interval | 15 |
| State | NV |
| Symbol | BIVIW |
| Total Cash | 13,098,976 |
| Total Cash Per Share | 1.737 |
| Total Debt | 295,717 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 34 |
| Website | https://bioviepharma.com |
| Zip | 89,703 |